Targeted therapies in melanoma

Surgical Oncology Clinics of North America

Volumn 24, Issue 2, 2015, Pages 347-358

  Moschos, Stergios J ^a   Pinnamaneni, Ramya ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

BRAF inhibitors; Immunotherapies; Melanoma; Next generation sequencing; Ocular melanoma

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; DABRAFENIB; DNA REPAIR PROTEIN; ENCORAFENIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUCLEIC ACID BINDING PROTEIN; RAS PROTEIN; RIBOCICLIB; SOTRASTAURIN; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; GENE TARGETING; HUMAN; MELANOMA; OCULAR MELANOMA; ONCOGENE C KIT; ONCOGENE H RAS; ONCOGENE N RAS; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; SKIN NEOPLASMS;

HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; SKIN NEOPLASMS;

EID: 84925943821     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.12.011     Document Type: Review

References (60)

1. Lee C., Collichio F., Ollila D., et al. Historical review of melanoma treatment and outcomes. Clin Dermatol 2013, 31:141-147.
2. Korn E.L., Liu P.Y., Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. JClin Oncol 2008, 26:527-534.
3. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
4. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
5. Alexandrov L.B., Nik-Zainal S., Wedge D.C., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
6. Jewell R., Conway C., Mitra A., et al. Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res 2010, 16:5211-5221.
7. Hodis E., Watson I.R., Kryukov G.V., et al. Alandscape of driver mutations in melanoma. Cell 2012, 150:251-263.
8. Watson I. Comprehensive molecular characterization of regional metastatic melanoma. Oral presentation at The Cancer Genome Atlas 3rd Annual Scientific Symposium, May 12-13. National Institutes of Health, Bethesda, MD, 2014.
9. Johnson G.L., Stuhlmiller T.J., Angus S.P., et al. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 2014, 20:2516-2522.
10. Poynter J.N., Elder J.T., Fullen D.R., et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006, 16:267-273.
11. Colombino M., Capone M., Lissia A., et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. JClin Oncol 2012, 30:2522-2529.
12. Nathanson K.L., Martin A.M., Wubbenhorst B., et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013, 19:4868-4878.
13. Ascierto P.A., Simeone E., Sileni V.C., et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. JTransl Med 2014, 12:116.
14. Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
15. Jeck W.R., Parker J., Carson C.C., et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res 2014, 27:653-663.
16. Sosman J.A., Moon J., Tuthill R.J., et al. Aphase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011, 117:4740-4746.
17. McArthur G.A., Chapman P.B., Robert C., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
18. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
19. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367:107-114.
20. Wilmott J.S., Long G.V., Howle J.R., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
21. Frederick D.T., Piris A., Cogdill A.P., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
22. Khalili J.S., Liu S., Rodriguez-Cruz T.G., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012, 18:5329-5340.
23. Koya R.C., Mok S., Otte N., et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012, 72:3928-3937.
24. Duncan J.S., Whittle M.C., Nakamura K., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
25. Angus SP, Stuhlmiller TJ, Reuther R, etal. Defining the adaptive kinome response to BRAF and MEK inhibition in melanoma (abstr 4761). AACR Annual Meeting, April 5-9. San Diego, CA, 2014.
26. Kim K, Amaravadi RK, Flaherty KT, etal. Significant long-term survival benefit demonstrated with vemurafenib in ongoing phase I study. Presented in the Society of Melanoma Research Annual Meeting, Nov 8-11. Hollywood, CA, 2012.
27. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEngl J Med 2010, 363:809-819.
28. Su F., Viros A., Milagre C., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. NEngl J Med 2012, 366:207-215.
29. Long G.V., Trefzer U., Davies M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
30. Dummer R., Goldinger S.M., Turtschi C.P., et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50:611-621.
31. Vaidhyanathan S., Mittapalli R.K., Sarkaria J.N., et al. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos 2014, 42:1292-1300.
32. Dummer R, Robert C, Nyakas M, etal. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma (abstr 9028). ASCO Annual Meeting, May 31-June 2. Chicago, IL, 2013.
33. Rodriguez-Viciana P., Sabatier C., McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004, 24:4943-4954.
34. Ascierto P.A., Schadendorf D., Berking C., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
35. Falchook G.S., Lewis K.D., Infante J.R., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
36. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. JClin Oncol 2006, 24:4340-4346.
37. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. NEngl J Med 2010, 363:2191-2199.
38. Harbour J.W., Onken M.D., Roberson E.D., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
39. Carvajal R.D., Sosman J.A., Quevedo J.F., et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014, 311:2397-2405.
40. Piperno-Neumann S, Kapiteijn E, Larkin JM, etal. Phase I dose-escalation study of the protein kinase C inhibitor AEB071 in patients with metastatic uveal melanoma (abstr 9030). ASCO Annual Meeting. Chicago, IL, 2014.
41. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367:1694-1703.
42. Long G.V., Stroyakovskiy D., Gogas H., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 371:1877-1888.
43. Ribas A., Gonzalez R., Pavlick A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014, 15:954-965.
44. Kefford R, Miller WH, Tan DS, etal. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors (abstr 9029). ASCO Annual Meeting, May 31-June 2. Chicago, IL, 2013.
45. Kwong L.N., Costello J.C., Liu H., et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18:1503-1510.
46. Sosman JA, Kittaneh M, Lolkema MP, etal. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity (abstr 9009). In ASCO (ed): ASCO 2014 Annual Meeting, May 30-June 3. Chicago, IL.
47. Ribas A., Hersey P., Middleton M.R., et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012, 18:336-341.
48. Mok S., Koya R.C., Tsui C., et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014, 74:153-161.
49. Liu C., Peng W., Xu C., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403.
50. Boni A., Cogdill A.P., Dang P., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
51. Puzanov I, Callahan MK, Linette GP, etal. Phase 1 study of the BRAF inhibitor dabrafenib with or without the MEK inhibitor trametinib in combination with ipilimumab for V600E/K mutation-positive unresectable or metastatic melanoma (abstr 2511), ASCO Annual Meeting, May 30-June 3. Chicago, IL, 2014.
52. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013, 19:1401-1409.
53. Chan M.M., Haydu L.E., Menzies A.M., et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 2014, 120:3142-3153.
54. Shi H., Hong A., Kong X., et al. Anovel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014, 4:69-79.
55. Trunzer K., Pavlick A.C., Schuchter L., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. JClin Oncol 2013, 31:1767-1774.
56. Algazi AP, Posch C, Ortiz-Urda S, etal. A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma (abstr 9101), ASCO Annual Meeting, May 30-June 3. Chicago, IL, 2014.
57. Mar V.J., Wong S.Q., Li J., et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 2013, 19:4589-4598.
58. Nissan M.H., Pratilas C.A., Jones A.M., et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014, 74:2340-2350.
59. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
60. Gao J., Aksoy B.A., Dogrusoz U., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1.